These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 6157064)

  • 1. Initial evaluation of human lymphoblastoid interferon in patients with advanced malignant disease.
    Priestman TJ
    Lancet; 1980 Jul; 2(8186):113-8. PubMed ID: 6157064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I pharmacotoxicology study of human fibroblast interferon in human cancers.
    McPherson TA; Tan YH
    J Natl Cancer Inst; 1980 Jul; 65(1):75-9. PubMed ID: 6156261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient tolerance to interferon: clinical and laboratory assessments.
    Fischl MA
    Med Clin North Am; 1986 May; Suppl():41-5. PubMed ID: 2426535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Side effects of long-term treatment with human leukocyte interferon.
    Ingimarsson S; Cantell K; Strander H
    J Infect Dis; 1979 Oct; 140(4):560-3. PubMed ID: 292735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I-II trials of poly IC stabilized with poly-L-lysine.
    Levine AS; Levy HB
    Cancer Treat Rep; 1978 Nov; 62(11):1907-12. PubMed ID: 728910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospectively randomized toxicity study of high-dose versus low-dose treatment strategies for lymphoblastoid interferon.
    Silver HK; Connors JM; Salinas FA
    Cancer Treat Rep; 1985; 69(7-8):743-50. PubMed ID: 4016785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and immunologic effects of recombinant leukocyte A interferon in eight patients with advanced cancer.
    Horning SJ; Levine JF; Miller RA; Rosenberg SA; Merigan TC
    JAMA; 1982 Mar; 247(12):1718-22. PubMed ID: 6174742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon and spontaneous cytotoxicity in man. II. Studies in patients receiving exogenous leukocyte interferon.
    Einhorn S; Blomgren H; Strander H
    Acta Med Scand; 1978; 204(6):477-83. PubMed ID: 282781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I trial of recombinant human gamma interferon (IFN-gamma 4A) in patients with advanced malignancy.
    Perez R; Lipton A; Harvey HA; Simmonds MA; Romano PJ; Imboden SL; Giudice G; Downing MR; Alton NK
    J Biol Response Mod; 1988 Jun; 7(3):309-17. PubMed ID: 3134513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I clinical investigation of homoharringtonine.
    Legha SS; Keating M; Picket S; Ajani JA; Ewer M; Bodey GP
    Cancer Treat Rep; 1984 Sep; 68(9):1085-91. PubMed ID: 6478448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of weekly high-dose human lymphoblastoid interferon.
    Connors JM; Silver HK
    Cancer Treat Rep; 1984 Sep; 68(9):1093-6. PubMed ID: 6478449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Interferons--its method of administration and adverse effect related to pharmacokinetics ].
    Furue H
    Gan To Kagaku Ryoho; 1984 Feb; 11(2):186-93. PubMed ID: 6582804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study of recombinant interferon-beta in patients with advanced malignant disease.
    Ravandi F; Estrov Z; Kurzrock R; Breitmeyer JB; Maschek BJ; Talpaz M
    Clin Cancer Res; 1999 Dec; 5(12):3990-8. PubMed ID: 10632330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer.
    Masters GA; Hoffman PC; Drinkard LC; Watson S; Samuels BL; Golomb HM; Vokes EE
    Semin Oncol; 1996 Apr; 23(2 Suppl 5):11-8. PubMed ID: 8610230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initial clinical studies with bruceantin.
    Bedikian AY; Valdivieso M; Bodey GP; Murphy WK; Freireich EJ
    Cancer Treat Rep; 1979; 63(11-12):1843-7. PubMed ID: 526918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon: pharmacokinetics and toxicity.
    Scott GM
    Philos Trans R Soc Lond B Biol Sci; 1982 Sep; 299(1094):91-107. PubMed ID: 6183699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of high-dose bolus interleukin-2 and interferon alfa-2a in patients with metastatic malignancy.
    Budd GT; Murthy S; Finke J; Sergi J; Gibson V; Medendorp S; Barna B; Boyett J; Bukowski RM
    J Clin Oncol; 1992 May; 10(5):804-9. PubMed ID: 1569452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Phase I study of human lymphoblastoid alpha-interferon on malignant tumor].
    Furue H
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):977-83. PubMed ID: 3963861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of multiple dose intramuscularly administered recombinant gamma interferon.
    Kurzrock R; Quesada JR; Talpaz M; Hersh EM; Reuben JM; Sherwin SA; Gutterman JU
    J Clin Oncol; 1986 Jul; 4(7):1101-9. PubMed ID: 3088221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I clinical trial of interleukin 2 and alpha-interferon: toxicity and immunologic effects.
    Budd GT; Osgood B; Barna B; Boyett JM; Finke J; Medendorp SV; Murthy S; Novak C; Sergi J; Tubbs R
    Cancer Res; 1989 Nov; 49(22):6432-6. PubMed ID: 2804986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.